Arpita Dutt | TalkMarkets | Page 6

Arpita Dutt

Analyst at Zacks Research Pvt. Ltd.
Contributor's Links: Zacks Investment Research
Arpita has been an equity analyst at Zacks Investment Research since March, 2004.
Following: 12 Followers: 1915

All Contributions

Latest Posts
81 to 92 of 92 Posts
<<< 1 ... 3 4 5 6
Kite Pharma (KITE) Q2 Loss Wider But Focus Is On KTE-C19
Tuesday, August 9, 2016 10:35 AM EDT
Kite’s research and development expenses shot up 185.5% from the year-ago period to $47.4 million in the reported quarter, general and administrative expenses were $23.5 million, up 140.6% from the year-ago period.
In this article: KITE Also: AMGN, CBM, HSKA
Read
Biotech Investing Guide: 3 Stocks To Buy And 3 To Avoid
Friday, March 11, 2016 2:10 PM EDT
Anyone interested in biotech stocks will know that it could be challenging to pick winners in this industry which is constantly growing and changing. We have zeroed in on 3 biotech stocks to buy and 3 to avoid.
In this article: ARNA, MNTA, REGN, AMGN, CELG, GILD Also: ABBV
Read
Pfizer Beats On Q4 Earnings, Revenues, Outlook Disappoints
Tuesday, February 2, 2016 10:42 AM EDT
While currency movement cut Pfizer’s fourth quarter revenues by 7% ($934 million), operational growth was 14% ($1.9 billion). International revenues declined 9% to $7.3 billion. Meanwhile, U.S. revenues grew 33% to $6.7 billion.
In this article: PFE Also: AGN, CELG, GILD
Read
5 Immunotherapy Stocks To Watch For Treating Cancer
Monday, October 19, 2015 7:20 AM EDT
Given the growing interest in immuno-oncology treatments, let’s take a look at some pharma and biotech companies that are looking to change the way we treat cancer.
In this article: AZN, INCY, AMGN, JUNO, KITE Also: MRK
Read
Five Stocks Searching For A Cancer Cure Right Now
Thursday, October 15, 2015 10:03 AM EDT
With companies working on bringing improved treatments with fewer side effects to market, it may be a good idea to keep an eye on these stocks which have the potential to revolutionize cancer treatment.
In this article: BMY, MRK, CLDX, AMGN, JUNO, KITE, BLUE
Read
5 Biotech Stocks Hit Hard By Hillary Clinton's Tweet
Wednesday, September 23, 2015 12:37 PM EDT
Healthcare stocks were hit hard yesterday following a tweet by Democratic Presidential candidate Hillary Clinton about the pricing of drugs.
In this article: REGN, AMGN, BIIB, GILD, VRTX
Read
J&J Beats On Q1 Earnings, Cuts View On Currency Woes
Tuesday, April 14, 2015 12:13 PM EDT
Johnson & Johnson (JNJ), the first among the large health care companies to report first quarter 2015 results, beat earnings expectations yet again.
In this article: JNJ, CAH, AMGN, BIIB
Read
J&J Beats On Q4 Earnings, Revenues Hit By Currency
Tuesday, January 20, 2015 9:16 AM EDT
Johnson & Johnson (JNJ), the first among the large health care companies to report fourth quarter and full year 2014 results, beat earnings expectations yet again.
In this article: JNJ, AMGN, CELG, ABBV
Read
3 Biotech Stocks That Soared Past Gilead In 2014
Wednesday, December 31, 2014 11:50 AM EDT
Gilead soared 100.11% in 2013 and is up around 30% year-to-date.
In this article: VRTX, GILD, ESRX, JNJ, ABBV, ACHN
Read
Actavis Strikes $66 Billion Deal For Botox Maker Allergan
Tuesday, November 18, 2014 5:01 PM EDT
With the Allergan acquisition, Actavis will be able to strengthen its global presence especially in Canada, Europe and Southeast Asia and other high-value growth markets like China, India, the Middle East and Latin America.
In this article: ACT, AGN, VRX, BIIB
Read
Teva Beats Q3 Earnings Expectations, Updates Outlook
Friday, October 31, 2014 5:52 PM EDT
Third quarter revenues remained flat at $5.058 billion, slightly below the Zacks Consensus Estimate of $5.100 billion.
In this article: TEVA
Read
Merck Tops On Q3 Earnings, Patent Expiries Hit Revenues
Monday, October 27, 2014 3:08 PM EDT
Merck & Co. reported third quarter 2014 earnings of 90 cents per share, beating the Zacks Consensus Estimate of 88 cents. Earnings, however, declined 2.2% from the year-ago period.
In this article: MRK
Read
81 to 92 of 92 Posts
<<< 1 ... 3 4 5 6